8-K: Taysha Gene Therapies Secures FDA Alignment for Pivotal Rett Syndrome Trial, Reports Strong Clinical Data for TSHA-102

Taysha Gene Therapies announced FDA alignment on a pivotal trial design for TSHA-102 in Rett syndrome, supported by positive clinical data from its REVEAL Part A trials and natural history data, while also suspending its $100 million ATM equity offering.

Summary

• Taysha Gene Therapies has received written alignment from the FDA on the design of its pivotal Part B trial for TSHA-102 in Rett syndrome.
• The pivotal trial will be a single-arm, open-label study intending to enroll 15 females aged 6 years and older (developmental plateau population), with each patient serving as their own control.
• The primary endpoint will be developmental milestone gain or regain, with a responder defined as gaining/regaining at least one defined developmental milestone.
• This trial design is supported by analysis of the International Rett Syndrome Foundation (IRSF) natural history study data, which showed a ~0% likelihood of developmental milestone gain/regain in untreated patients aged 6 years and older.
• Positive clinical data from Part A of the REVEAL Phase 1/2 trials (N=10, aged 6-21 years) showed 100% of patients gained or regained at least one developmental milestone post-TSHA-102 treatment.
• A total of 22 developmental milestones were achieved across the 10 patients, including improvements in communication, fine motor, and gross motor functions.
• The high dose cohort (1x10^15 total vg) achieved a 100% responder rate 25% faster than the low dose cohort (5.7x10^14 total vg), with dose-dependent effects deepening over time.
• TSHA-102 demonstrated statistically significant mean improvements in Revised Motor Behavior Assessment (R-MBA) scores compared to natural history data at 6 months (p < 0.0001) and 12 months (p = 0.0123).
• Clinician Global Impression-Improvement (CGI-I) scores showed early global improvement, with the high dose cohort achieving an average score of 1.0 ("very much improved") at 9 months, compared to 2.8 for the low dose cohort.
• TSHA-102 was generally well tolerated, with no treatment-related serious adverse events (SAEs) or dose-limiting toxicities (DLTs) observed in 12 patients.
• The company has suspended and terminated the prospectus for its At-The-Market (ATM) equity offering, which allowed for the sale of up to $100,000,000 of common stock. The underlying Sales Agreement remains in effect, but no further sales will occur without a new prospectus.

Sentiment

Score: 9

Explanation: The document conveys a highly positive sentiment due to strong clinical data for TSHA-102, FDA alignment on a pivotal trial design, and a favorable safety profile. The termination of the ATM prospectus is a minor negative, but the extended cash runway mitigates immediate concerns, and the overall progress in a high-unmet-need disease is very encouraging.

Positives

• FDA alignment on pivotal Part B trial design for TSHA-102, indicating a clear regulatory path forward.
• Positive clinical data from REVEAL Part A trials, with 100% of patients (N=10) gaining/regaining at least one developmental milestone.
• Observed dose-dependent effects, with the high dose outperforming the low dose and achieving a 100% responder rate 25% faster.
• Statistically significant improvements in R-MBA scores compared to natural history data at 6 months (p < 0.0001) and 12 months (p = 0.0123).
• High dose cohort showed "very much improved" average CGI-I score (1.0) at 9 months.
• Favorable safety profile with no treatment-related SAEs or DLTs observed.
• Validation of TSHA-102's potential as a disease-modifying therapy for Rett syndrome, addressing the genetic root cause.
• Cash resources are projected to support operations into Q4 2026.

Risks

• The ATM Sales Agreement remains in effect, but no sales can be made until a new prospectus or registration statement is filed, which could delay future capital raises if needed.
• The option agreement with Astellas for TSHA-102 could lead to disputes regarding whether its exercise constitutes a change of control, potentially resulting in reputational harm and litigation.
• While TSHA-102 has shown positive results, there is no guarantee of reproducibility or durability of favorable results in larger or longer-term trials.
• Regulatory approval from the FDA or equivalent foreign agencies is not guaranteed.
• The company is substantially dependent on TSHA-102 as its sole product candidate in clinical development.

Future Outlook

Taysha Gene Therapies anticipates submitting the pivotal Part B trial protocol and statistical analysis plan (SAP) as an amendment to its Investigational New Drug (IND) application in the current quarter (Q2 2025). Trial initiation activities for the pivotal program are expected in the third quarter of 2025. The company's current cash resources are projected to support planned operating expenses and capital requirements into the fourth quarter of 2026. Additionally, Taysha expects to deliver the Rett Data Package to Astellas in mid-2025, which will trigger a 90-day option period for Astellas to exercise its exclusive license option for TSHA-102.

Management Comments

• "Our rigorous analysis of the robust natural history study dataset demonstrated that after six years of age, the likelihood of achieving defined developmental milestones across the core functional domains of Rett syndrome is highly improbable. Therefore, it is quite striking that we observed a 100% responder rate following treatment with TSHA-102, with all pediatric, adolescent and adult patients across varying disease severity gaining or regaining one or more developmental milestone that represents activities of daily living that are important to caregivers and clinicians. We believe this objective and clinically meaningful primary endpoint has the potential to redefine treatment expectations and expand the possibilities of gene therapy for patients with Rett syndrome." Sean P. Nolan, Chairman and CEO of Taysha.
• "We believe aligning with the FDA on key elements of our proposed pivotal trial design validates these important findings that underpin our pivotal trial design and strengthen our conviction in the transformative potential of TSHA-102. Importantly, this progress sets us on an efficient and expeditious path to potentially deliver TSHA-102 to patients and families suffering from this devastating disease with high unmet need." Sean P. Nolan, Chairman and CEO of Taysha.
• "This innovative analysis and cumulative incidence models of the Rett syndrome natural history dataset help shape our understanding of the disease trajectory by establishing that the likelihood of gain and regain of developmental milestones is predictable after six years of age. Importantly, these data allow us to objectively measure how transformative therapies impact functional aspects of the disease that are essential to activities of daily living." Dr. Jeffrey Neul, M.D., Ph.D., Rett Specialist.
• "On behalf of IRSF, I want to thank the families, clinicians, and researchers whose dedication made the Rett syndrome Natural History Study possible. Their participation provided a deeper understanding of how Rett progresses over time, insights that are now helping shape meaningful clinical outcome measures and could someday lead to new treatments." Laura Hameed, CEO of the International Rett Syndrome Foundation (IRSF).

Industry Context

Taysha Gene Therapies operates in the highly specialized and competitive field of gene therapy for severe monogenic central nervous system diseases. The focus on Rett syndrome, a rare neurodevelopmental disorder with no approved disease-modifying therapies addressing its genetic root cause, highlights a significant unmet medical need. The successful commercial launch and uptake of DAYBUE (trofinetide) by Acadia Pharmaceuticals, a symptomatic treatment for Rett syndrome, underscores the market demand and the high caregiver burden associated with the disease. Taysha's TSHA-102, designed as a one-time gene therapy addressing the root cause, positions it as a potentially transformative treatment in this landscape, aiming to offer a more fundamental solution compared to existing symptomatic management.

Comparison to Industry Standards

• Taysha's 100% responder rate in Part A of the REVEAL trial (N=10) for TSHA-102, where patients gained/regained at least one developmental milestone, is highly significant given the natural history data indicating a near 0% likelihood of such gains in untreated patients aged 6 years and older. This contrasts sharply with the typical progression of Rett syndrome, where developmental plateaus and regressions are expected.
• The statistically significant improvements in R-MBA scores and the "very much improved" CGI-I scores observed with TSHA-102 suggest a clinical benefit that goes beyond symptomatic management, aiming to alter the disease course, which is a key differentiator from currently available treatments like Acadia Pharmaceuticals' DAYBUE (trofinetide), which focuses on symptomatic improvement.
• The FDA's alignment on a single-arm, open-label pivotal trial design, with patients serving as their own control, is a notable regulatory achievement for a rare disease gene therapy, reflecting the strength of the natural history data and the observed clinical effects. This streamlined approach could accelerate the path to potential approval compared to traditional placebo-controlled trials.
• The safety profile of TSHA-102, with no treatment-related SAEs or DLTs, is favorable compared to the general risks associated with gene therapies, which can include immune responses, off-target effects, or severe adverse events.

Related Party Transactions

• Taysha has an existing option agreement with Astellas, granting Astellas an exclusive option to an exclusive license for TSHA-102. This agreement includes certain rights for Astellas related to a change of control of Taysha.

Stakeholder Impact

• Shareholders: Positive impact due to significant clinical progress and regulatory clarity for TSHA-102, potentially increasing the company's valuation and long-term prospects. The suspension of the ATM offering removes immediate dilution risk, though future capital raises are still possible.
• Patients and Caregivers (Rett Syndrome): Highly positive impact as TSHA-102 shows potential to be a transformative, disease-modifying treatment, offering hope for improved functional outcomes and quality of life in a disease with high unmet medical need.
• Employees: Positive impact due to clear progress in the lead clinical program, potentially enhancing job security and morale.
• Regulatory Authorities (FDA): Continued collaboration and alignment on trial design, demonstrating a constructive relationship.
• International Rett Syndrome Foundation (IRSF): Positive collaboration, as their natural history data was instrumental in shaping the pivotal trial design.

Next Steps

• Submit pivotal Part B trial protocol and associated Statistical Analysis Plan (SAP) as an amendment to the Investigational New Drug (IND) application in Q2 2025.
• Host three oral presentations related to TSHA-102 at the 2025 IRSF Rett Syndrome Scientific Meeting in Boston from June 9-11, 2025.
• Initiate pivotal Part B trial site activation and trial initiation activities in Q3 2025.
• Deliver the Rett Data Package to Astellas in mid-2025, triggering a 90-day option period for Astellas to exercise its exclusive license option for TSHA-102.

Key Dates

Recommendation

Keywords

Rett Syndrome, Gene Therapy, TSHA-102, Clinical Trial, FDA Alignment, Pivotal Trial, REVEAL Trial, AAV9, MECP2, Biotechnology, Rare Disease, Orphan Drug, RMAT, Nasdaq: TSHA, Taysha Gene Therapies, IRSF, Natural History Data, Developmental Milestones, R-MBA, CGI-I, ATM Offering, Capital Raise